Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Paeds Vivashaematology-oncology-and-transfusion

Paeds Vivas · haematology-oncology-and-transfusion

Sickle cell disease: diagnosis and health maintenance: Viva

Branching clinical structured oral on the diagnosis and health maintenance of sickle cell disease in children, covering the newborn-screen diagnosis and the haemoglobin electrophoresis pattern, the p.Glu6Val mutation and the sickling cascade, the penicillin prophylaxis schedule, the encapsulated-organ immunisation, the hydroxyurea backbone from nine months, and the annual transcranial Doppler with chronic transfusion, appraising the PROPS, Multicenter Study of Hydroxyurea, STOP, STOP II and TWiTCH trials.

branching clinical structured oral4 min readVerification in progress

Target exams

RACP DWERACP DCEMRCPCH Clinical
On this page
Study tools

Target exams

RACP DWERACP DCEMRCPCH Clinical
Prompt
An eight-week-old boy is found on routine newborn screening to have a haemoglobin pattern of FS, confirmed on repeat testing as HbSS. He is well and feeding normally. The examiner asks how you confirm the diagnosis, what the molecular basis is, what you start now, when you start hydroxyurea and how you monitor it, and how you appraise the trial evidence for stroke prevention.

This is a newborn-screen diagnosis of sickle cell anaemia, HbSS, in a well eight-week-old boy. The structured oral runs from the confirmation of the diagnosis through the molecular basis, the immediate prophylaxis, the hydroxyurea decision, and the stroke-prevention strategy, and it ends with the trial evidence. [5]

Opening: confirm the diagnosis

Examiner. The newborn screen shows an FS pattern. What does that mean, and how do you confirm it? [5]

Candidate. The FS pattern on high-performance liquid chromatography means the child has haemoglobin F and haemoglobin S with little or no haemoglobin A, which is the pattern of HbSS, sickle cell anaemia. I confirm it with a repeat test on a fresh sample by the same method, and I do not need further testing unless the result is ambiguous, in which case deoxyribonucleic acid testing of the HBB gene settles the mutation. The child is well at eight weeks because fetal haemoglobin protects the cell, and the complications begin only as it falls through the first year. [5]

Paediatrics Fellowship Pro

Continue reading

You have read the opening of this viva. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship library.

Sign in to continueSee pricing
References5ShowHide
  1. [1]Gaston MH, Verter JI, Woods G Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med, 1986.PMID 3086721
  2. [2]Charache S, Terrin ML, Moore RD Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med, 1995.PMID 7715639
  3. [3]Adams RJ, McKie VC, Hsu L Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med, 1998.PMID 9647873
  4. [5]Yawn BP, Buchanan GR, Afenyi-Annan AN Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA, 2014.PMID 25203083
  5. [7]Ware RE, Davis BR, Schultz WH Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet, 2016.PMID 26670617
Paediatrics Fellowship Pro

$29/ monthor $279 / year

The complete Paediatrics Fellowship library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousSickle cell acute complications: Vivahaematology-oncology-and-transfusionNextThalassaemia syndromes: Vivahaematology-oncology-and-transfusion